That's the spin. In fact it has become extremely divisive. They
are supposed to be the elite of Singapore research and take
precedence over everyone else. Those not in biopolis feel slighted
and will not cooperate with those in the elite group. Doctors in
the two health clusters compete with each other and so refuse to
work with each other. It is easier to collaborate with an overseas
researcher than it is with someone in the other cluster. As for
biopolis, everyone (not in it) hates them.
Remember during the SARS crisis the government claimed to be able
to produce a diagnostic kit within days, which stretched to weeks
and months. Where are the thousands of dollars that were supposed
to come from this research? The doctors who were treating SARS
patients felt they were the heartlanders who took the risk and did
the work whilst the elite got the attention. Do you expect good
co-operation with the elite?
I am not surprised when nobody wants to work together. It's a
replay of the elite versus the heartlanders...
By business culture, I mean the emphasis on the bottomline. In
commerce, the bottomline is dollars and cents; whilst in research,
the common perception is that it is publications. By focusing on
short term goals such as number of publications, we are telling
researchers to produce papers rather than adopt innovative lines of
inquiry that may not easily get a paper published. Innovation is
always risky. Many Nobel prize winners have been considered daft
because their ideas were too radical for the time. If a scientist
knows that his pay may be cut if he does not have a publication by
the end of the year, he will work on something far less
risky.
What I mean is, I can easily work on something 'safe' to guarantee
a publication but that does not translate into tangible benefit for
Singapore or the world at large. But if I work on a totally novel
idea, I might lose my funding and even my job. Consider this, the
drugs we use to treat many cancers today are essentially no
different from what we used 20 years ago, despite the millions of
publications in cancer research. (There are few recent novel
therapies based on targeted anti-cancer effect but these are
expensive and are not available to the vast majority of our
patients, unless they are very rich).
This problem is not unique to Singapore. There is a very perceptive
article in Fortune magazine that puts my point across much better
than I can:
"According to PubMed, the NCI's online database, the cancer
research community has published 1.56 million papersthat's right:
1.56 million!largely on this circuitry and its related genes in
hundreds of journals over the years. Many of the findings are
shared at the 100-plus international congresses, symposiums, and
conventions held each year.
Yet somehow, along the way, something important has gotten lost.
The search for knowledge has become an end unto itself rather than
the means to an end. And the research has become increasingly
narrow, so much so that physician-scientists who want to think
systemically about cancer or the organism as a wholeor who might
have completely new approachesoften can't get funding..."
(THE WAR ON CANCER: Why We're Losing the War on Cancerand How to
Win It, Fortune magazine, 22 Mar 2004).
You can read more at this link:
http://www.fortune.com/fortune/articles/0,15114,598425,00.html